Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development and sales milestones.
Rolland-Yves Mauvernay, president and founder of Debiopharm Group, said: “We are very excited to continue our collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimization and preclinical work.
“The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and haematological malignancies.”